A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker

Molecular and Cellular Proteomics

Volumn 10, Issue 12, 2011, Pages

  Besson, Damien ^a   Pavageau, Aude Hélène ^a   Valo, Isabelle ^b   Bourreau, Anthony ^a   Bélanger, Audrey ^a   Eymerit Morin, Caroline ^a   Moulière, Alice ^a   Chassevent, Agnès ^b   Boisdron Celle, Michelle ^a   Morel, Alain ^a   Solassol, Jerôme ^c   Campone, Mario ^d   Gamelin, Erick ^a   Barré, Benjamin ^a   Coqueret, Olivier ^a   Guette, Catherine ^a  

^a Nantes St Herblain and Centre de Recherche en Cancérologie et Immunologie   (France)

^b CENTRE PAUL PAPIN   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLFACTOMEDIN 4; PARAFFIN; PROTEIN; PROTEOME; RAS PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; OLFM4 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DATA BASE; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; ADENOCARCINOMA; ADENOMA; ADULT; CARCINOMA; CELL STRAIN HT29; COLORECTAL TUMOR; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; GLYCOSYLATION; LASER CAPTURE MICRODISSECTION; METABOLISM; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SECRETION;

ADENOCARCINOMA; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOSYLATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HT29 CELLS; HUMANS; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEOME; PROTEOMICS; RAS PROTEINS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 83055168484     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M111.009712     Document Type: Article

References (61)

1. Cunningham, D., Atkin, W., Lenz, H. J., Lynch, H. T., Minsky, B., Nordlinger, B., and Starling, N. (2010) Colorectal cancer. Lancet 375, 1030-1047
2. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010) Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300
3. Huang, C. S., Lal, S. K., and Farraye, F. A. (2005) Colorectal cancer screening in average risk individuals. Cancer Causes Control 16, 171-188 (Pubitemid 40685059)
4. van Rossum, L. G., van Rijn, A. F., Laheij, R. J., van Oijen, M. G., Fockens, P., van Krieken, H. H., Verbeek, A. L., Jansen, J. B., and Dekker, E. (2008) Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135, 82-90 (Pubitemid 351899018)
5. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., and Bos, J. L. (1988) Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525-532
6. Pino, M. S., and Chung, D. C. (2010) The chromosomal instability pathway in colon cancer. Gastroenterology 138, 2059-2072
7. Clevers, H. (2006) Wnt/beta-catenin signaling in development and disease. Cell 127, 469-480
8. Reya, T., and Clevers, H. (2005) Wnt signalling in stem cells and cancer. Nature 434, 843-850 (Pubitemid 40558990)
9. Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., and Clevers, H. (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611
10. van der Flier, L. G., and Clevers, H. (2009) Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu. Rev. Physiol. 71, 241-260
11. Phelps, R. A., Chidester, S., Dehghanizadeh, S., Phelps, J., Sandoval, I. T., Rai, K., Broadbent, T., Sarkar, S., Burt, R. W., and Jones, D. A. (2009) A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 137, 623-634
12. Lièvre, A., Bachet, J. B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., André, T., Bibeau, F., Diebold, M. D., Rougier, P., Ducreux, M., Tomasic, G., Emile, J. F., Penault-Llorca, F., and Laurent-Puig, P. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379 (Pubitemid 351171687)
13. Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M. B., Harpole, D., Lancaster, J. M., Berchuck, A., Olson, J. A., Jr., Marks, J. R., Dressman, H. K., West, M., and Nevins, J. R. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (Pubitemid 43128862)
14. Chang, J. T., Carvalho, C., Mori, S., Bild, A. H., Gatza, M. L., Wang, Q., Lucas, J. E., Potti, A., Febbo, P. G., West, M., and Nevins, J. R. (2009) A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol. Cell 34, 104-114
15. Garman, K. S., Acharya, C. R., Edelman, E., Grade, M., Gaedcke, J., Sud, S., Barry, W., Diehl, A. M., Provenzale, D., Ginsburg, G. S., Ghadimi, B. M., Ried, T., Nevins, J. R., Mukherjee, S., Hsu, D., and Potti, A. (2008) A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc. Natl. Acad. Sci. U.S.A. 105, 19432-19437
16. Crawford, N. P., Colliver, D. W., and Galandiuk, S. (2003) Tumor markers and colorectal cancer: Utility in management. J. Surg. Oncol. 84, 239-248 (Pubitemid 37484790)
17. Sidransky, D. (2002) Emerging molecular markers of cancer. Nat. Rev. Cancer 2, 210-219
18. Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., and Topolcan, O. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 43, 1348-1360 (Pubitemid 46874070)
19. Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., and Bast, R. C., Jr. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24, 5313-5327 (Pubitemid 46631379)
20. Jimenez, C. R., Knol, J. C., Meijer, G. A., and Fijneman, R. J. (2010) Proteomics of colorectal cancer: Overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J. Proteomics 73, 1873-1895
21. Alfonso, P., Cañamero, M., Fernández-Carbonié, F., Núñez, A., and Casal, J. I. (2008) Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J. Proteome Res. 7, 4247-4255
22. Bi, X., Lin, Q., Foo, T. W., Joshi, S., You, T., Shen, H. M., Ong, C. N., Cheah, P. Y., Eu, K. W., and Hew, C. L. (2006) Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: Mechanism of tumorigenesis. Mol. Cell. Proteomics 5, 1119-1130 (Pubitemid 43985935)
23. Rho, J. H., Qin, S., Wang, J. Y., and Roehrl, M. H. (2008) Proteomic expression analysis of surgical human colorectal cancer tissues: Upregulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J. Proteome Res. 7, 2959-2972
24. Ducoux-Petit, M., Uttenweiler-Joseph, S., Brichory, F., Bousquet- Dubouch, M. P., Burlet-Schiltz, O., Haeuw, J. F., and Monsarrat, B. (2008) Scaled-down purification protocol to access proteomic analysis of 20S proteasome from human tissue samples: Comparison of normal and tumor colorectal cells. J. Proteome Res. 7, 2852-2859
25. Roessler, M., Rollinger, W., Palme, S., Hagmann, M. L., Berndt, P., Engel, A. M., Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmüller, H., Rüschoff, J., Henkel, T., Rohr, G., Rossol, S., Rösch, W., Langen, H., Zolg, W., and Tacke, M. (2005) Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 11, 6550-6557 (Pubitemid 41338994)
26. Roessler, M., Rollinger, W., Mantovani-Endl, L., Hagmann, M. L., Palme, S., Berndt, P., Engel, A. M., Pfeffer, M., Karl, J., Bodenmüller, H., Rüschoff, J., Henkel, T., Rohr, G., Rossol, S., Rösch, W., Langen, H., Zolg, W., and Tacke, M. (2006) Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics 5, 2092-2101 (Pubitemid 44817021)
27. Kim, H. J., Kang, H. J., Lee, H., Lee, S. T., Yu, M. H., Kim, H., and Lee, C. (2009) Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res. 8, 1368-1379
28. Ma, Y., Peng, J., Liu, W., Zhang, P., Huang, L., Gao, B., Shen, T., Zhou, Y., Chen, H., Chu, Z., Zhang, M., and Qin, H. (2009) Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol. Cell. Proteomics 8, 1878-1890
29. Xu, B. J., Li, J., Beauchamp, R. D., Shyr, Y., Li, M., Washington, M. K., Yeatman, T. J., Whitehead, R. H., Coffey, R. J., and Caprioli, R. M. (2009) Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS. Mol. Cell. Proteomics 8, 936-945
30. Ernoult, E., Gamelin, E., and Guette, C. (2008) Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Sci. 6, 27
31. Ernoult, E., Bourreau, A., Gamelin, E., and Guette, C. (2010) A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation. J. Biomed. Biotechnol. 2010, 927917
32. Barker, N., van Es, J. H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P. J., and Clevers, H. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007 (Pubitemid 350014593)
33. van der Flier, L. G., Haegebarth, A., Stange, D. E., van de Wetering, M., and Clevers, H. (2009) OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology 137, 15-17
34. Shilov, I. V., Seymour, S. L., Patel, A. A., Loboda, A., Tang, W. H., Keating, S. P., Hunter, C. L., Nuwaysir, L. M., and Schaeffer, D. A. (2007) The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol. Cell. Proteomics 6, 1638-1655 (Pubitemid 47506173)
35. Schwacke, J. H., Hill, E. G., Krug, E. L., Comte-Walters, S., and Schey, K. L. (2009) iQuantitator: A tool for protein expression inference using iTRAQ. BMC Bioinformatics 10, 342
36. Grant, J. E., Bradshaw, A. D., Schwacke, J. H., Baicu, C. F., Zile, M. R., and Schey, K. L. (2009) Quantification of protein expression changes in the aging left ventricle of Rattus norvegicus. J. Proteome Res. 8, 4252-4263
37. Zeeberg, B. R., Qin, H., Narasimhan, S., Sunshine, M., Cao, H., Kane, D. W., Reimers, M., Stephens, R. M., Bryant, D., Burt, S. K., Elnekave, E., Hari, D. M., Wynn, T. A., Cunningham-Rundles, C., Stewart, D. M., Nelson, D., and Weinstein, J. N. (2005) High-Throughput GoMiner, an "industrial-strength " integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics 6, 168
38. Ekins, S., Nikolsky, Y., Bugrim, A., Kirillov, E., and Nikolskaya, T. (2007) Pathway mapping tools for analysis of high content data. Methods Mol. Biol. 356, 319-350
39. Sobin, L. H., Gospodarowicz, M. K., and C., W. (eds.) (2009) TNM Classification of Malignant Tumours, 7th Ed., Wiley-Blackwell, Chichester, UK
40. Bienvenu, F., Barré, B., Giraud, S., Avril, S., and Coqueret, O. (2005) Transcriptional regulation by a DNA-associated form of cyclin D1. Mol. Biol. Cell 16, 1850-1858 (Pubitemid 40471954)
41. Courapied, S., Sellier, H., de Carn é Trécesson, S., Vigneron, A., Bernard, A. C., Gamelin, E., Barré, B., and Coqueret, O. (2010) The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J. Biol. Chem. 285, 26765-26778
42. Courapied, S., Cherier, J., Vigneron, A., Troadec, M. B., Giraud, S., Valo, I., Prigent, C., Gamelin, E., Coqueret, O., and Barré, B. (2010) Regulation of the Aurora-A gene following topoisomerase I inhibition: Implication of the Myc transcription factor. Mol. Cancer 9, 205
43. Vigneron, A., Gamelin, E., and Coqueret, O. (2008) The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res. 68, 815-825 (Pubitemid 351206759)
44. Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., Kagnoff, M. F., and Karin, M. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (Pubitemid 39061110)
45. Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, O., Schwitalla, S., Matthews, V., Schmid, R. M., Kirchner, T., Arkan, M. C., Ernst, M., and Greten, F. R. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102
46. Mathew, R., Karp, C. M., Beaudoin, B., Vuong, N., Chen, G., Chen, H. Y., Bray, K., Reddy, A., Bhanot, G., Gelinas, C., Dipaola, R. S., Karantza-Wadsworth, V., and White, E. (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137, 1062-1075
47. Barré, B., and Perkins, N. D. (2010) The Skp2 promoter integrates signaling through the NF-kappaB, p53, and Akt/GSK3beta pathways to regulate autophagy and apoptosis. Mol. Cell 38, 524-538
48. de Carn é Trécesson, S., Guillemin, Y., Bélanger, A., Bernard, A. C., Preisser, L., Ravon, E., Gamelin, E., Juin, P., Barré, B., and Coqueret, O. (2011) Escape from p21-mediated oncogene-induced senescence leads to cell dedifferenciation and dependency on anti-apoptotic Bcl-xL and Mcl1 proteins. J. Biol. Chem. 286, 12825-12838
49. Bernards, R. (2010) It's diagnostics, stupid. Cell 141, 13-17
50. Chin, L., and Gray, J. W. (2008) Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (Pubitemid 351483369)
51. van't Veer, L. J., and Bernards, R. (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452, 564-570
52. Sawyers, C. L. (2008) The cancer biomarker problem. Nature 452, 548-552
53. Pichler, P., Köcher, T., Holzmann, J., Mazanek, M., Taus, T., Ammerer, G., and Mechtler, K. (2010) Peptide labeling with isobaric tags yields higher identification rates using iTRAQ 4-plex compared to TMT 6-plex and iTRAQ 8-plex on LTQ Orbitrap. Anal. Chem 82, 6549-6558
54. Liu, W., Lee, H. W., Liu, Y., Wang, R., and Rodgers, G. P. (2010) Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2′- deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. Blood 116, 4938-4947
55. Chen, L., Li, H., Liu, W., Zhu, J., Zhao, X., Wright, E., Cao, L., Ding, I., and Rodgers, G. P. (2011) Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1. Carcinogenesis 32, 986-994
56. Grover, P. K., Hardingham, J. E., and Cummins, A. G. (2010) Stem cell marker olfactomedin 4: Critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev. 29, 761-775
57. White, E., and Lowe, S. W. (2009) Eating to exit: Autophagy-enabled senescence revealed. Genes Dev. 23, 784-787
58. Thiele, C. J., Li, Z., and McKee, A. E. (2009) On Trk: The TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin. Cancer Res. 15, 5962-5967
59. Vanhecke, E., Adriaenssens, E., Verbeke, S., Meignan, S., Germain, E., Berteaux, N., Nurcombe, V., Le Bourhis, X., and Hondermarck, H. (2011) Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin. Cancer Res. 17, 1741-1752
60. Liu, W., Liu, Y., Zhu, J., Wright, E., Ding, I., and Rodgers, G. P. (2008) Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin. Cancer Res. 14, 1041-1049 (Pubitemid 351302549)
61. Roninson, I. B. (2003) Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705-2715